Cocrystal Pharma, Inc.
corporate_fare Company Profile
Cocrystal Pharma, Inc. (NASDAQ:COCP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for COCP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for COCP spans 8-K, 10-Q, SCHEDULE 13D/A, DEF 14A.
Recent high-impact activity:
- Cocrystal Pharma Completes Dosing in Phase 1b Norovirus Study for CDI-988; No Serious Adverse Events Reported
- Cocrystal Pharma Q2 10-Q: Going Concern Persists Despite $5M OPKO Placement
- Phillip Frost Lifts Cocrystal Stake to 13.9% with $80K in Open-Market Buys
- Cocrystal Pharma Secures $5M Private Placement from OPKO Health, Extending Cash Runway
- Cocrystal Pharma Appoints Biopharma Veteran James Sapirstein as New CEO
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for COCP, detected from its recent SEC filings · based on capital-structure filings through 2026-05-15.
Going Concern Warning Reiterated · Limited Cash Runway
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →